

Market Applicability						
Market	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X

Zytiga (abiraterone acetate)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Zytiga (abiraterone acetate)	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Zytiga (abiraterone acetate) may be approved if the following are met:

- I. Individual is using in combination with prednisone;

AND

- II. Individual is diagnosed with one of the following:
 - A. Metastatic castration-resistant* prostate cancer (CRPC); **OR**
 - B. Individual is diagnosed with Metastatic castration-sensitive prostate cancer (CSPC);

AND

- III. One of the following:
 - A. Individual is concomitantly receiving a gonadotropin-releasing hormone (GnRH) analog (e.g. Lupron (leuprolide, Zoladex (goserelin), Trelstar (triptorelin), Vantas (histrelin), Firmagon (degarelix); **OR**
 - B. Individual has had a bilateral orchiectomy.

Requests for Zytiga (abiraterone acetate) may not be approved for the following:

- I. Individual is using the alternative agent (Yonsa (abiraterone acetate) with methylprednisolone for metastatic CRPC.

*Castration-resistant refers to disease progression following either surgically or medically-induced methods of castration. Medically-induced methods of castration include luteinizing hormone-releasing hormone (LHRH) agonists (such as leuprolide and goserelin) or LHRH antagonists (such as degarelix).

Key References:

CRX-ALL-0595-20

PAGE 1 of 1 09/11/2020

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability						
Market	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2019. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: July 22, 2019.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.
5. NCCN Clinical Practice Guidelines in Oncology™. © 2019 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on July 22, 2019.
 - a. Prostate Cancer. V2.2019. Revised April 17, 2019.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.